Cochlear Limited (COH.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
222.75+2.79 (+1.27%)
At close: 4:10PM AEDT
| Previous close | 219.96 |
| Open | 222.87 |
| Bid | 222.64 x 10000 |
| Ask | 222.81 x 3400 |
| Day's range | 220.88 - 225.86 |
| 52-week range | 176.68 - 257.76 |
| Volume | 105,643 |
| Avg. volume | 124,735 |
| Market cap | 14.651B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 44.85 |
| EPS (TTM) | 4.97 |
| Earnings date | 19 Aug 2021 |
| Forward dividend & yield | 2.80 (1.26%) |
| Ex-dividend date | 23 Sept 2021 |
| 1y target est | 223.68 |
- Simply Wall St.
We Discuss Why Cochlear Limited's (ASX:COH) CEO May Deserve A Higher Pay Packet
Shareholders will probably not be disappointed by the robust results at Cochlear Limited ( ASX:COH ) recently and they...
- PR Newswire
Cochlear announces FDA approval and FDA clearance of first-of-its-kind Remote Care capabilities for Nucleus and Baha Systems
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval and clearance in the last month for its Cochlear™ Remote Assist solution in the Nucleus® and Baha® Systems. The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.
- Simply Wall St.
Cochlear Limited (ASX:COH) Shares Could Be 34% Above Their Intrinsic Value Estimate
How far off is Cochlear Limited ( ASX:COH ) from its intrinsic value? Using the most recent financial data, we'll take...
© 2021 Verizon Media. All rights reserved.
